{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:07:16Z","timestamp":1695575236852},"reference-count":119,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":1817,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"SIE, SIES and GITMO societies"},{"name":"Celgene and Munipharma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1093\/annonc\/mdu152","type":"journal-article","created":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T03:44:53Z","timestamp":1397187893000},"page":"2339-2350","source":"Crossref","is-referenced-by-count":13,"title":["SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias"],"prefix":"10.1016","volume":"25","author":[{"given":"P.","family":"Corradini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Barosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Billio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gallamini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Pimpinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.L.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu152_bb0010","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0015","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0020","first-page":"460","article-title":"The NIH Consensus Development Program. The evolution of guidelines","volume":"12","author":"Ferguson","year":"1996","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1093\/annonc\/mdu152_bb0025","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br J Med"},{"key":"10.1093\/annonc\/mdu152_bb0030","series-title":"Group Techniques for Program Planning: a Guide to Nominal Group and Delphi Processes","author":"Delbecq","year":"1975"},{"key":"10.1093\/annonc\/mdu152_bb0035","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0040","first-page":"1063","article-title":"Bone marrow that is positive for Epstein-Barr virus encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer\/T-cell lymphoma, nasal type","volume":"90","author":"Huang","year":"2005","journal-title":"Haema-tologica"},{"key":"10.1093\/annonc\/mdu152_bb0045","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2010-08-303305","article-title":"Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphoma by massively parallel genomic sequencing","volume":"117","author":"Feldman","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0050","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","article-title":"Genome-wide analysis reveals structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas","volume":"120","author":"Vasmatzis","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0055","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0060","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (TCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0065","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathological prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0070","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajh.23422","article-title":"The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer\/T-cell lymphoma, nasal type","volume":"88","author":"Li","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdu152_bb0075","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0080","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/annonc\/mdp412","article-title":"When do we need central nervous system prophylaxis in patients with extranodal NK\/T-cell lymphoma, nasal type?","volume":"21","author":"Kim","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0085","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2967\/jnumed.112.113399","article-title":"The role of 18F-FDG PET\/CT for initial staging of nasal type natural killer\/T-cell lymphoma: a comparison with conventional staging methods","volume":"54","author":"Moon","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/mdu152_bb0090","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.3452.3452","article-title":"Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis","volume":"110","author":"AbouYabis","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0095","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0100","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T-cell lymphoma. Results of the randomized phase III trial GOLEAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu152_bb0105","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1365-2141.2011.08634.x","article-title":"Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers","volume":"153","author":"Niitsu","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu152_bb0110","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0115","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results from the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0120","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"102","author":"Tilly","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2141.2006.06124.x","article-title":"Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study","volume":"134","author":"Sung","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu152_bb0130","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0135","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdu152_bb0140","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"22","author":"Kluin-Nelemans","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0145","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00277-013-1880-4","article-title":"CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial","volume":"92","author":"Binder","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdu152_bb0150","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.3348.3348","article-title":"A pilot trial of Campath-1H and dose-adjusted EPOCH in CD52-expressing aggressive T-cell malignancies","volume":"106","author":"Janik","year":"2005","journal-title":"Blood"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdu152_bb0155","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1200\/jco.2010.28.15_suppl.8045","article-title":"Phase II study of denileukindiftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial","volume":"28","author":"Foss","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0160","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu152_bb0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-005-0136-y","article-title":"CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas","volume":"58","author":"Kim","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdu152_bb0170","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdu152_bb0175","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2005.05478.x","article-title":"The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas","volume":"129","author":"Sonnen","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu152_bb0180","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0185","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0190","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0195","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1200\/JCO.2004.12.032","article-title":"Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"22","author":"Mounier","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0200","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","article-title":"High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"20","author":"Nickelsen","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0205","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1660.1660","article-title":"Aggressive primary chemotherapy plus autologous stem cell transplantation improves outcome for peripheral T cell lymphomas compared with CHOP-like regimens","volume":"114","author":"Sieniawski","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0210","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbmt.2008.11.010","volume":"15","author":"Yang","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mdu152_bb0215","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.11173","article-title":"The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing\/refractory peripheral T-cell lymphoma","volume":"92","author":"Rodr\u00edguez","year":"2007","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdu152_bb0220","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdu152_bb0225","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/annonc\/mdh471","article-title":"All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"15","author":"Mounier","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0230","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0235","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3109\/10428194.2011.561388","article-title":"Long-term outcomes of patients with newly diagnosed extranodal natural killer\/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience","volume":"52","author":"Huang","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdu152_bb0240","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.oraloncology.2006.11.020","article-title":"Combined chemoradiation for the management of nasal natural killer (NK)\/T-cell lymphoma: elucidating the significance of systemic chemotherapy","volume":"44","author":"Guo","year":"2008","journal-title":"Oral Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0245","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.radonc.2009.08.045","article-title":"A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE\/IIE extranodal NK\/T-cell lymphoma, nasal type in the upper aerodigestive tract","volume":"93","author":"Ma","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0250","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0255","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.1998.16.1.70","article-title":"Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients","volume":"16","author":"Cheung","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0260","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0360-3016(02)02916-4","article-title":"Early stage nasal NK\/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality","volume":"54","author":"Cheung","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdu152_bb0265","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/annonc\/mdp418","article-title":"Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type","volume":"21","author":"Suzuki","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0270","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0275","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.ijrobp.2010.10.040","article-title":"Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK\/T-cell lymphoma","volume":"82","author":"Li","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdu152_bb0280","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/cncr.11908","article-title":"Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer\/T-cell or T-cell lymphoma","volume":"100","author":"Li","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu152_bb0285","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdh143","article-title":"Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)\/T-cell lymphoma: a single institute survey in Taiwan","volume":"15","author":"You","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0290","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.clon.2008.05.011","article-title":"A clinical study of 115 patients with extranodal natural killer\/T-cell lymphoma, nasal type","volume":"20","author":"Wu","year":"2008","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"10.1093\/annonc\/mdu152_bb0295","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijrobp.2007.05.073","article-title":"Early or up-front radiotherapy improved survival of localized extranodal NK\/T-cell lymphoma, nasal-type in the upper aerodigestive tract","volume":"70","author":"Huang","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdu152_bb0300","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/cncr.21656","article-title":"Extranodal natural killer\/T-cell lymphoma, nasaltype: the significance of radiotherapeutic parameters","volume":"106","author":"Isobe","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu152_bb0305","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.radonc.2006.03.014","article-title":"Analyses of dose-response in radiotherapy for patients with mature T\/NK-cell lymphomas according to the WHO classification","volume":"79","author":"Sakata","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0310","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","article-title":"Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma","volume":"24","author":"Li","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0315","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00277-012-1630-z","article-title":"Retrospective analysis of treatment outcomes for extranodal NK\/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK\/T-cell lymphoma (ENKL)","volume":"92","author":"Lee","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdu152_bb0320","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ijrobp.2011.02.039","article-title":"Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK\/T-cell lymphoma","volume":"82","author":"Wang","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdu152_bb0325","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2679.2679","article-title":"Complete remission after first-line radio plus chemotherapy is enough to improve survival in extra nodal NK\/T cell lymphoma","volume":"118","author":"Chauchet","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jjco\/hyi006","article-title":"Treatment outcome of angiocentric T-cell and NK\/T-cell lymphoma, nasaltype: radiotherapy versus chemoradiotherapy","volume":"35","author":"Kim","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0335","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1182\/blood-2008-05-160176","article-title":"Clinical features and treatment outcome of nasal-type NK\/T-cell lymphoma of Waldeyer ring","volume":"112","author":"Li","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0340","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","article-title":"Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211","volume":"27","author":"Yamaguchi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0345","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study","volume":"27","author":"Kim","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0350","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/cncr.27752","article-title":"First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE\/IIE extranodal natural killer\/T-cell lymphoma","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu152_bb0355","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1002\/cncr.26629","article-title":"Phase 2 trial of \u2018sandwich\u2019 L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer\/T-cell lymphoma","volume":"118","author":"Jiang","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu152_bb0360","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.bmt.1705349","article-title":"High-dose chemotherapy with autologous stem cell transplantation in extranodal NK\/T-cell lymphoma: a retrospective comparison with non-transplantation cases","volume":"37","author":"Kim","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdu152_bb0365","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s12032-010-9532-1","article-title":"Allogeneic haematopoietic stem cell transplantation as a salvage strategy for relapsed or refractory nasal NK\/T-cell lymphoma","volume":"28","author":"Li","year":"2011","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0370","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3109\/10428194.2010.487958","article-title":"Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer\/T cell lymphoma, nasal type","volume":"51","author":"Yokoyama","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdu152_bb0375","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05651.x","article-title":"Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms","volume":"130","author":"Murashige","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu152_bb0380","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/10428190127500","article-title":"High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas","volume":"42","author":"Takenaka","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdu152_bb0385","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705244","article-title":"Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms","volume":"37","author":"Suzuki","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdu152_bb0390","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3109\/10428194.2011.572322","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer\/T-cell lymphoma, nasal type","volume":"52","author":"Ennishi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdu152_bb0395","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrclinonc.2009.169","article-title":"Gamma-delta T-cell lymphomas","volume":"6","author":"Tripodo","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0400","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1346-8138.2011.01291.x","article-title":"Subcutaneous panniculitis-likeT-cell lymphoma: successful treatment with systemic steroid alone","volume":"39","author":"Jang","year":"2012","journal-title":"J Dermatol"},{"key":"10.1093\/annonc\/mdu152_bb0405","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clml.2011.06.016","article-title":"Bexarotene is active against subcutaneous panniculitis-likeT-cell lymphoma in adult and pediatric populations","volume":"12","author":"Mehta","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1093\/annonc\/mdu152_bb0410","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5045\/kjh.2012.47.2.146","article-title":"Cyclosporine A treatment for relapsed subcutaneous panniculitis-likeT-cell lymphoma: a case with long-term follow-up","volume":"47","author":"Go","year":"2012","journal-title":"Korean J Hematol"},{"key":"10.1093\/annonc\/mdu152_bb0415","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000323565","article-title":"Cyclosporine A for chemotherapy-resistant subcutaneous panniculitis-likeT cell lymphoma with hemophagocytic syndrome","volume":"126","author":"Mizutani","year":"2011","journal-title":"Acta Haematol"},{"key":"10.1093\/annonc\/mdu152_bb0420","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/cncr.20502","article-title":"Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature","volume":"101","author":"Go","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu152_bb0425","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0430","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1200\/JCO.2012.41.5976","article-title":"Romidepsin is effective in subcutaneous panniculitis-likeT-cell lymphoma","volume":"30","author":"Bashey","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0435","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1748-717X-7-118","article-title":"Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia","volume":"7","author":"Hauswald","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0440","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/COC.0b013e31825494d3","article-title":"Treatment of mycosis fungoides with total skin electron beam: response and relapse by ethnicity and sex","volume":"36","author":"Hinds","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0445","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3109\/0284186X.2011.585999","article-title":"Total skin electron beam therapy for cutaneous T-cell lymphoma: a nationwide cohort study from Denmark","volume":"50","author":"Lindahl","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0450","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archdermatol.2011.98","article-title":"The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides","volume":"147","author":"Navi","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1093\/annonc\/mdu152_bb0455","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1016\/j.ijrobp.2011.01.023","article-title":"Revisiting low-dose total skin electron beam therapy in mycosis fungoides","volume":"81","author":"Harrison","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdu152_bb0460","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1093\/annonc\/mdu152_bb0465","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1093\/annonc\/mdu152_bb0470","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu152_bb0475","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu152_bb0480","first-page":"338","article-title":"Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin\u2014consensus of the lymphoma group of the Working Group Dermatologic Oncology","volume":"11","author":"Assaf","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1093\/annonc\/mdu152_bb0485","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archdermatol.2011.232","article-title":"High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response","volume":"147","author":"Raphael","year":"2011","journal-title":"Arch Dermatol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdu152_bb0490","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/12034754030070S403","article-title":"Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma","volume":"7","author":"Richardson","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"10.1093\/annonc\/mdu152_bb0495","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/archderm.138.8.1054","article-title":"Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1093\/annonc\/mdu152_bb0500","first-page":"1","article-title":"Extracorporeal photophoresis: an evidence-based analysis","volume":"6","author":"Health Quality Ontario","year":"2006","journal-title":"Ont Health Technol Assess Ser"},{"key":"10.1093\/annonc\/mdu152_bb0505","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0510","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0515","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukindiftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0520","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0525","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilidehydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu152_bb0530","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2012.06.002","article-title":"Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: a systematic review","volume":"85","author":"Schlaak","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdu152_bb0535","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Duarte","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0540","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0545","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0550","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0555","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdn726","article-title":"Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study","volume":"20","author":"Kim","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0560","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdu152_bb0565","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350","volume":"119","author":"Mahadevan","year":"2013","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu152_bb0570","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu152_bb0575","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","article-title":"Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma","volume":"150","author":"D'Amore","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu152_bb0580","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0585","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu152_bb0590","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2011.08651.x","article-title":"Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)","volume":"153","author":"Dearden","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu152_bb0595","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdu152_bb0600","doi-asserted-by":"crossref","first-page":"vi149","DOI":"10.1093\/annonc\/mdt242","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Willemze","year":"2013","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419368954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419368954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/12\/2339\/845110\/mdu152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:33:20Z","timestamp":1624520000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419368954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":119,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0923753419368954"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu152","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}